Bright Minds Biosciences (DRUG) Research & Development (2020 - 2026)
Bright Minds Biosciences' (DRUG) quarterly Research & Development came in at $9.5 million in Q1 2026, up 432.65% YoY from $1.8 million in Q1 2025, and up 134.39% on a QoQ basis from $4.1 million in Q4 2025.
Bright Minds Biosciences (DRUG) Research & Development (2020 - 2026) Analysis & Trends
Bright Minds Biosciences (DRUG) has 7 years of Research & Development data on file, last reported at $9.5 million in Q1 2026.
- Quarterly Research & Development rose 432.65% year-over-year to $9.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.0 million (up 683.14% YoY) and the FY2025 annual result came in at $8.1 million, up 831.13% from the prior year.
- Research & Development improved to $9.5 million in Q1 2026, from $4.1 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $9.5 million in Q1 2026 to a low of -$414373.2 in Q2 2024.
- A 5-year average of $1.9 million and a median of $1.1 million in 2022 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2024 — Research & Development tumbled 152.98% — and 2025, when it surged 2188.44%.
- Tracing DRUG's Research & Development over 5 years: stood at $1.1 million in 2022, then declined by 16.29% to $900190.9 in 2023, then dropped by 16.87% to $748325.8 in 2024, then soared by 442.43% to $4.1 million in 2025, then jumped by 134.39% to $9.5 million in 2026.
- The last three Research & Development figures came in at $9.5 million (Q1 2026), $4.1 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Bright Minds Biosciences | 733.05 Mn | 733.05 Mn | - | 9.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.51 Mn |
| Dec 31, 2025 | 4.06 Mn |
| Sep 30, 2025 | 3.48 Mn |
| Jun 30, 2025 | 1.94 Mn |
| Mar 31, 2025 | 1.79 Mn |
| Dec 31, 2024 | 748,325.78 |
| Sep 30, 2024 | 304,990.54 |
| Jun 30, 2024 | -414,373.17 |
| Mar 31, 2024 | 78,055.47 |
| Dec 31, 2023 | 900,190.92 |
| Sep 30, 2023 | 814,045.11 |
| Jun 30, 2023 | 782,185.04 |
| Mar 31, 2023 | 1.03 Mn |
| Dec 31, 2022 | 1.08 Mn |
| Sep 30, 2022 | 1.95 Mn |
| Jun 30, 2022 | 1.61 Mn |
| Mar 31, 2022 | 2.96 Mn |
| Dec 31, 2021 | 3.05 Mn |
| Sep 30, 2021 | 4.72 Mn |
| Jun 30, 2021 | 2.20 Mn |